In detail, the following questions will be answered:~Do distinct metabolic phenotypes (with respect to insulin secretion, insulin sensitivity, circulating free fatty acids and ectopic lipid storage, especially in the liver) determine myocardial infarct size and decline of contractile function of the remote myocardium?~Which factors modify the progression of the disease (insulin resistance, ectopic lipid storage, subclinical inflammation, abnormal energy metabolism)? Patients are thoroughly examined at baseline and one year after STEMI.~Can we identify risk profiles and their relevance for development of diabetes-associated complications as well as long-term progression of diabetes?~Can we improve risk assessment algorithms for targeted therapy in line with Precision Medicine?
The aim of the prospective observational DISTEMI-Study in patients with and without Diabetes mellitus after new onset of ST-Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to characterize in detail the clinical, metabolical, immunological and vascular phenotype, investigate the interplay beween myocardial remodelling and the metabolic phenotype, monitor the progression of the disease and compare the phenotype of STEMI patients with diabetes mellitus to glucose tolerant patients.